IQVIA Joins Forces with FDA to Improve Understanding of COVID-19’s Community Impact
IQVIA announced a scientific partnership with the U.S. Food and Drug Administration that will serve to provide timely analytics from [...]
[Podcast] Telehealth, Standardizing Care, and Drug Prices in Oncology With Dr. Vincent Rajkumar
Tune to this podcast for a discussion on telehealth in oncology with Vincent Rajkumar, MD. As he lends his insights [...]
[Webinar] How can VA/HTA Inform Policy Interventions and Public Health Investment?
Join ISPOR and the Innovation and Value Initiative (IVI) on October 23, 2020 for the fourth instalment of a free [...]
What Do Payers Really Want From Health Systems Data?
Although there is an abundance of clinical data available to health-system specialty pharmacies, many pharmacies in outcomes-based contracts continue to [...]
Kanata’s Evidence Partners Shine Through Their COVID-19 Research
Demand for Evidence Partners’ DistillerSR, which streamlines the medical research process for academics and health organizations has skyrocketed during the [...]
Town Hall Meeting Sparks Thought-provoking Discussion About US Healthcare Spending
A diverse group of health care experts and stakeholders participated in the Going Below The Surface (GBTS) Forum’s first ever [...]
Racial Biases Persist in Widely-used Analytics Software
According to a recent article published by Casey Ross of Stat News, infusion of bias into decisions about who should [...]
Pay-for-Performance Program Increased Evidence-Based Prescribing of Cancer Drugs
Increased prescribing rates of evidence-based cancer drugs may be achieved without a concomitant change in total spending on care through [...]
[Webinar] Digital Innovation and the Field Medical Role: Where Medical Affairs Can Show its Mettle During COVID-19
Tune in tomorrow, Oct 15 at 10:00 AM EST, for a special 75-minute MAPS Global Town Hall in which a [...]
How Should Value-based Care Be Implemented?
Value-based care is already proven to work, so the question now is how to best implement it. One possibility would [...]
What’s the Evidence for HTA?
In this blog, Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate, explains NICE’s role as co-host of [...]
Amazon, Apple, Facebook, and Google Target the Health Insurance Market
According to a recent analysis and report published by CB Insights, Amazon, Apple, Facebook, and Google have been able to [...]
The Shifting Evidence Landscape in the Era of COVID-19
There is extreme pressure on governments, researchers, and health care providers to deliver effective, evidence-based approaches to the prevention, detection, [...]
What Post-pandemic changes Would Patients Like to See Continue?
CoverMyMeds recently performed a patient survey which also heavily informed the COVID-19 & Medication Access report. In the survey, patients [...]
[Webinar] Patient-Focused Medicines Development During COVID-19
The COVID-19 pandemic has turned the lives of many patients upside down by adding additional layers of complexity. How exactly [...]
[Virtual Seminar] Statistics for the Non-Statistician
Join Steven Wachs on Thursday, October 15, 2020 at 11:00 AM EDT for a 6-Hour Virtual Seminar on Statistics for [...]
Ethnoracial Disparities Pervasive in Clinical Research
As clinical trials are the gold standard for evidence-based medicine, it is essential for researchers to be as inclusive as [...]
Researchers Perform Integrative Review of Managed Entry Agreements
Managed entry agreements (MEAs) are of group of instruments designed to reduce the budget impact, uncertainty, and risk of expensive [...]
What COVID-19 Can Teach Us About Real World Data
Due to the urgent need to characterize and track the spread of COVID-19, good healthcare data have been highly sought [...]
WHO’s New Pricing Policy Guideline Makes Medicines More Affordable
A new WHO guideline aims to help governments overcome the barrier of high prices for pharma products, enabling them to [...]
[Webinar] Bayesian Statistics and FDA Regulatory Acceptability
Bayesian statistics have been used in regulatory submissions to the Food and Drug Administration (FDA) for over 15 years in [...]
Size Doesn’t Matter: A Small Biotech Plays Big with Payer Engagement
Last month, Dr. Patti Peeples, CEO of HealthEconomics.Com, interviewed Allen Lising on how Xcenda’s FormularyDecisions™ is used early in drug development [...]
[Webinar] Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient-Centered?
Researchers, value assessors, and the patient community agree that traditional means of value assessment often do not factor in the [...]
Geographic Bias Present in Medical AI Tools
Historically, diversity has not been a serious consideration in the minds of researchers when studying new medications. Most clinical trials [...]
How Can Specialty Pharmacy Thrive in the New Era of Value?
The days of fee-for-service health care are coming to an end, with value-based initiatives that improve patient outcomes, reduce cost, [...]